Anlikang: The targets of the three pipelines are relatively clear, with a certain probability of druggability.

Anglikang stated during a recent institutional research survey that all three pipelines are currently in the preclinical PCC stage and are progressing as planned. From PCC to IND, work including candidate molecule confirmation, pharmaceutical and non-clinical studies must be completed. At the same time, the production timeline for proprietary ionizable lipids will also be aligned with the R&D and production progress of Kerey Biotech. The entire cycle is significantly affected by the technical route and experimental results and normally takes about 1 to 1.5 years. Based on current experimental data, the targets of the three pipelines are relatively clear and have a certain probability of druggability.